Sun Pharma Q2 net profit up 70%
Shares of Sun Pharmaceutical Industries rallied more than 6% to Rs 516.10 apiece on Wednesday after the drug maker clocked 70% on-year increase in net profit to Rs 1,813 crore in the three months ended September.
Sun Pharma, India’s largest drugmaker had reported a net loss of Rs 1,656 crore in the preceding quarter.
Other expenses declined 3% to Rs 2,392 crore and other income rose by 28% to Rs 256 crore, aiding profitability.
Revenue rose 5% over a year earlier to Rs 8,553 crore, compared with the estimated Rs 8,302 crore. That’s also a 13% rise over the April-June quarter.
Sun Pharma’s operating profit rose 30% to Rs 2,310 crore, against the Rs 1,861-crore forecast.
Margin improved to 27% over the year earlier 22%.
Sales and gross profit of Taro Pharmaceutical Industries, its US subsidiary, dropped 25.7% and 16.3% year-on-year to $142.8 million and $81.6 million, respectively, in the quarter ended September. The earnings and sales of Taro, however, improved over the preceding three months.
The US business accounts for more than 30% of Sun Pharma’s overall consolidated sales. Taro Pharma contributes nearly half of the parent’s total US formulation sales
Revenue from India business grew 1% to Rs 2,531 crore.
US-finished dosage sales remained flat compared with a year earlier at $335 million; grew 19% compared with Q1FY21. Emerging market sales rose 4.5% to $210 million. Rest of the world sales at $178 million, up 10%. API business grew 9% to Rs 510 crore.
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.